ArticlePLoS clinical trials2006
RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection.
Article in PLoS clinical trials, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 79 citations in OpenAlex.
- Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine.The New England journal of medicine · 2015Trial
- Trial
- Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications.The Journal of infectious diseases · 2013Trial
- A field trial to assess a blood-stage malaria vaccine.The New England journal of medicine · 2011Trial
- Multiplicity of Plasmodium falciparum infection following intermittent preventive treatment in infants.Malaria journal · 2010Trial
- Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine.Malaria journal · 2010Trial
- Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.PloS one · 2009Trial
- Can incorporating genotyping data into efficacy estimators improve efficiency of early phase malaria vaccine trials?Malaria journal · 2023Article
- Drug resistance and vaccine target surveillance of Plasmodium falciparum using nanopore sequencing in Ghana.Nature microbiology · 2023Article
- Malaria Genomics, Vaccine Development, and Microbiome.Pathogens (Basel, Switzerland) · 2023Review
- A chemokine-fusion vaccine targeting immature dendritic cells elicits elevated antibody responses to malaria sporozoites in infant macaques.Scientific reports · 2021Article
- Population genetic analysis of the Plasmodium falciparum circumsporozoite protein in two distinct ecological regions in Ghana.Malaria journal · 2020Article
- Age-dependent carriage of alleles and haplotypes of Plasmodium falciparum sera5, eba-175, and csp in a region of intense malaria transmission in Uganda.Malaria journal · 2020Article
- RTS,S/AS01 vaccine (Mosquirix™): an overview.Human vaccines & immunotherapeutics · 2020Article
- The Delay in the Licensing of Protozoal Vaccines: A Comparative History.Frontiers in immunology · 2020Review
- Article
- RTS,S/AS01 malaria vaccine mismatch observed among Plasmodium falciparum isolates from southern and central Africa and globally.Scientific reports · 2018Article
- [The RTS,S/AS01 malaria vaccine in children aged 5-17 months at first vaccination].The Pan African medical journal · 2018Review
- Review
- Vaccines against malaria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 6 countries.
Funding
Abstract
objectiveThe candidate malaria vaccine RTS,S/AS02A is a recombinant protein containing part of the circumsporozoite protein (CSP) sequence of Plasmodium falciparum, linked to the hepatitis B surface antigen and formulated in the proprietary adjuvant system AS02A. In a recent trial conducted in children younger than age five in southern Mozambique, the vaccine demonstrated significant and sustained efficacy against both infection and clinical disease. In a follow-up study to the main trial, breakthrough infections identified in the trial were examined to determine whether the distribution of csp sequences was affected by the vaccine and to measure the multiplicity of infecting parasite genotypes.
designP. falciparum DNA from isolates collected during the trial was used for genotype studies.
settingThe main trial was carried out in the Manhiça district, Maputo province, Mozambique, between April 2003 and May 2004.
participantsChildren from the two cohorts of the main trial provided parasite isolates as follows: children from Cohort 1 who were admitted to hospital with clinical malaria; children from Cohort 1 who were parasite-positive in a cross-sectional survey at study month 8.5; children from Cohort 2 identified as parasite-positive during follow-up by active detection of infection. OUTCOME: Divergence of DNA sequence encoding the CSP T cell-epitope region sequence from that of the vaccine sequence was measured in 521 isolates. The number of distinct P. falciparum genotypes was also determined.
resultsWe found no evidence that parasite genotypes from children in the RTS,S/AS02A arm were more divergent than those receiving control vaccines. For Cohort 1 (survey at study month 8.5) and Cohort 2, infections in the vaccine group contained significantly fewer genotypes than those in the control group, (p = 0.035, p = 0.006), respectively, for the two cohorts. This was not the case for children in Cohort 1 who were admitted to hospital (p = 0.478).
conclusionsRTS,S/AS02A did not select for genotypes encoding divergent T cell epitopes in the C-terminal region of CSP in this trial. In both cohorts, there was a modest reduction in the mean number of parasite genotypes harboured by vaccinated children compared with controls, but only among those with asymptomatic infections.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.